The science.
Namida Lab designed Auria to be simple, convenient, and non-invasive.
Our biological breast cancer screening test empowers women to actively participate in their journey to finding answers and allows us to detect breast cancer early.
Tears are a clean, easy fluid allowing us to get to the proteins of interest faster.
Dynamic Range
We can get to low molecular weight proteins in high concentrations quicker and easier by using tears.
Low Cost
Tear-based biological screening doesn’t require extensive processing in our CLIA-Certified lab.
Self-Collection
Non-invasive collection allows for accessible and convenient at-home testing.
Auria has a sensitivity of
92%
This means out of 100 women with breast cancer, Auria would classify 92 of those women as medium or high.
We have preferentially selected our algorithm to have a higher sensitivity in order to reduce the number of missed cancers.
For more information, read the White Papers and Peer-Reviewed Publications.
Large components in blood can mask small cancer markers. These components are not present in tears, making small cancer markers much easier to spot.
Is Auria for me?
Auria is intended for women ages 30 and over. Auria is for all bodies & all breasts: dense breasts, implants, screening avoidant, or lack of access. For more information on whether you are a good candidate for Auria, visit our About Auria page.
Auria is not intended for women with an unevaluated palpable mass or area of concern in their breast tissue. It is also not intended for women who no longer have breast tissue.
Clinical data is not yet available for patients who are currently being treated for breast cancer, have been recently diagnosed with cancer, or are being monitored for reoccurrence.
Current data only supports biological females at birth with breast tissue. Upcoming clinical trials with our LGBTQIA+ community and biological males at birth is underway to expand Auria’s availability.
How accurate is Auria?
Auria has a sensitivity of 92% which means out of 100 women with breast cancer, Auria would classify 92 of those women as clinically significant (or above the diagnostic threshold); the remaining 8 are identified as negative.
Auria has a specificity of 58%, which means out of 100 normal women, Auria would classify 58 of them as negative.
We have preferentially selected our algorithm to have a higher sensitivity in order to reduce the number of missed cancers (i.e. false negatives). As with all lab-developed tests, continued use of our assay will allow for optimization of the diagnostic parameters.
